The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice

Metabolism: Clinical and Experimental

Volumn 62, Issue 5, 2013, Pages 734-742

  Hamada, Yoji ^a   Nagasaki, Hiroshi ^b   Fuchigami, Masahiro ^c   Furuta, Shinji ^c   Seino, Yusuke ^a   Nakamura, Jiro ^d   Oiso, Yutaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^d AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alpha glucosidase inhibitors; Bile acids; Glucagon like peptide 1; Miglitol; Obesity

Indexed keywords

ADIPOCYTOKINE; GLUCAGON LIKE PEPTIDE 1; LIVER ENZYME; MIGLITOL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BILE ACID METABOLISM; CAVA VEIN; CONTROLLED STUDY; DRUG EFFECT; EPIDIDYMIS FAT; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HOMEOSTASIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PORTAL VEIN BLOOD; PRIORITY JOURNAL; UPREGULATION; WEIGHT CHANGE; WEIGHT GAIN;

1-DEOXYNOJIRIMYCIN; ALPHA-GLUCOSIDASES; ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICE; OBESITY; RATS; RATS, WISTAR;

EID: 84876676770     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.10.015     Document Type: Article

References (35)

1. A. Lee, P. Patrick, J. Wishart, M. Horowitz, and J.E. Morley The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics Diabetes Obes Metab 4 2002 329 335 (Pubitemid 34947095)
2. T. Narita, H. Yokoyama, and R. Yamashita Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients Diabetes Obes Metab 14 2012 283 287
3. M. Arakawa, C. Ebato, and T. Mita Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects Metabolism 57 2008 1299 1306
4. J.L. Chiasson, R.G. Josse, and R. Gomis Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial JAMA 290 2003 486 494 (Pubitemid 37430502)
5. J.J. Holst, T. Vilsbøll, and C.F. Deacon The incretin system and its role in type 2 diabetes mellitus Mol Cell Endocrinol 297 2009 127 136
6. Y. Fujita, R.D. Wideman, and M. Speck Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo Am J Physiol Endocrinol Metab 296 2009 E473 E479
7. H.P. Bartram, W. Scheppach, C. Heid, C. Fabian, and H. Kasper Effect of starch malabsorption on fecal bile acids and neutral sterols in humans: possible implications for colonic carcinogenesis Cancer Res 51 1991 4238 4242
8. F.K. Knop Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab 299 2010 E10 E13
9. M. Watanabe, S.M. Houten, and C. Mataki Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 439 2006 484 489 (Pubitemid 43152840)
10. R. Cao, Z.X. Cronk, and W. Zha Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway J Lipid Res 51 2010 2234 2244
11. H. Ueda, H. lkegami, and E. Yamato The NSY mouse: A new animal model of spontaneous NIDDM with moderate obesity Diabetologia 38 1995 503 508
12. J.Y. Chiang Bile acids: Regulation of synthesis J Lipid Res 50 2009 1955 1966
13. P.A. Dawson, T. Lan, and A. Rao Bile acid transporters J Lipid Res 50 2009 2340 2357
14. S.M. Houten, M. Watanabe, and J. Auwerx Endocrine functions of bile acids EMBO J 25 2006 1419 1425
15. C. Thomas, A. Gioiello, and L. Noriega TGR5-mediated bile acid sensing controls glucose homeostasis Cell Metab 10 2009 167 177
16. M. Kobayashi, H. Ikegami, and T. Fujisawa Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin Diabetes 56 2007 239 247
17. L. Chen, J. McNulty, and D. Anderson Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats J Pharmacol Exp Ther 334 2010 164 170
18. Q. Shang, M. Saumoy, J.J. Holst, G. Salen, and G. Xu Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1 Am J Physiol Gastrointest Liver Physiol 298 2010 G419 G424
19. B. Staels, and V.A. Fonseca Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration Diabetes Care 32 Suppl 2 2009 S237 S245
20. V.A. Fonseca, Y. Handelsman, and B. Staels Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence Diabetes Obes Metab 12 2010 384 392
21. C. Beysen, E.J. Murphy, and K. Deines Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study Diabetologia 55 2012 432 442
22. L. Chen, X. Yao, and A. Young Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes Am J Physiol Endocrinol Metab 302 2012 E68 E76
23. S. Cipriani, A. Mencarelli, G. Palladino, and S. Fiorucci FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats J Lipid Res 51 2010 771 784
24. T. Tsuchida, M. Shiraishi, T. Ohta, K. Sakai, and S. Ishii Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice Metabolism 61 2012 944 953
25. N. Fukaya, K. Mochizuki, and Y. Tanaka The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats Eur J Pharmacol 624 2009 51 57
26. M. Koyama, R. Wada, and H. Mizukami Inhibition of progressive reduction of islet beta-cell mass in spontaneously diabetic Goto-Kakizaki rats by alpha-glucosidase inhibitor Metabolism 49 2000 347 352 (Pubitemid 30146566)
27. J.L. Chiasson, R.G. Josse, and R. Gomis Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data Diabetologia 47 2004 969 975 (Pubitemid 38918154)
28. R. Kawamori, N. Tajima, and Y. Iwamoto Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance Lancet 373 2009 1607 1614
29. Y. Ihara, S. Toyokuni, and K. Uchida Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes Diabetes 48 1999 927 932 (Pubitemid 29153099)
30. L. Li, W. El-Kholy, C.J. Rhodes, and P.L. Brubaker Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B Diabetologia 48 2005 1339 1349 (Pubitemid 41186100)
31. M. Cornu, J.Y. Yang, E. Jaccard, C. Poussin, C. Widmann, and B. Thorens Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop Diabetes 58 2009 1816 1825
32. Y. Moritoh, K. Takeuchi, and M. Hazama Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice Diabetes Obes Metab 12 2010 224 233
33. I.R. Popescu, A. Helleboid-Chapman, and A. Lucas The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity FEBS Lett 584 2010 2845 2851
34. M. Düfer, K. Hörth, and R. Wagner Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition Diabetes 61 2012 1479 1489
35. N.M. Whalley, L.E. Pritchard, D.M. Smith, and A. White Processing of proglucagon to GLP-1 in pancreatic α-cells: Is this a paracrine mechanism enabling GLP-1 to act on β-cells? J Endocrinol 211 2011 99 106